Home >> Pharmaceuticals >> Food & Beverage >>

Endocyte, Inc. - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 46 | Code: MRS - 35151

Endocyte, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Endocyte, Inc. - Product Pipeline Review - 2015’, provides an overview of the Endocyte, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Endocyte, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Endocyte, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Endocyte, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Endocyte, Inc.’s pipeline products

Reasons to buy

- Evaluate Endocyte, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Endocyte, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Endocyte, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Endocyte, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Endocyte, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Endocyte, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Endocyte, Inc. Snapshot 6
Endocyte, Inc. Overview 6
Key Information 6
Key Facts 6
Endocyte, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Endocyte, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Endocyte, Inc. - Pipeline Products Glance 12
Endocyte, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Endocyte, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Endocyte, Inc. - Drug Profiles 16
vintafolide 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
EC-1169 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
EC-1456 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
EC-0371 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
EC-0531 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
EC-1069 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
EC-1496 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
EC-1669 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
EC-1744 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
EC-1788 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
EC-1953 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Small Molecule to Target Folate Receptor Beta for Solid Tumors 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Small Molecules to Target Folate Receptors for Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Endocyte, Inc. - Pipeline Analysis 32
Endocyte, Inc. - Pipeline Products by Target 32
Endocyte, Inc. - Pipeline Products by Route of Administration 33
Endocyte, Inc. - Pipeline Products by Molecule Type 34
Endocyte, Inc. - Pipeline Products by Mechanism of Action 35
Endocyte, Inc. - Recent Pipeline Updates 36
Endocyte, Inc. - Dormant Projects 42
Endocyte, Inc. - Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
vintafolide 43
Endocyte, Inc. - Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Endocyte, Inc., Key Information 6
Endocyte, Inc., Key Facts 6
Endocyte, Inc. - Pipeline by Indication, 2015 8
Endocyte, Inc. - Pipeline by Stage of Development, 2015 10
Endocyte, Inc. - Monotherapy Products in Pipeline, 2015 11
Endocyte, Inc. - Phase II, 2015 12
Endocyte, Inc. - Phase I, 2015 13
Endocyte, Inc. - Preclinical, 2015 14
Endocyte, Inc. - Discovery, 2015 15
Endocyte, Inc. - Pipeline by Target, 2015 32
Endocyte, Inc. - Pipeline by Route of Administration, 2015 33
Endocyte, Inc. - Pipeline by Molecule Type, 2015 34
Endocyte, Inc. - Pipeline Products by Mechanism of Action, 2015 35
Endocyte, Inc. - Recent Pipeline Updates, 2015 36
Endocyte, Inc. - Dormant Developmental Projects,2015 42
Endocyte, Inc. - Discontinued Pipeline Products, 2015 43
Endocyte, Inc., Other Locations 44

List of Figures
Endocyte, Inc. - Pipeline by Top 10 Indication, 2015 8
Endocyte, Inc. - Pipeline by Stage of Development, 2015 10
Endocyte, Inc. - Monotherapy Products in Pipeline, 2015 11
Endocyte, Inc. - Pipeline by Top 10 Target, 2015 32
Endocyte, Inc. - Pipeline by Top 10 Route of Administration, 2015 33
Endocyte, Inc. - Pipeline by Top 10 Molecule Type, 2015 34
Endocyte, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 35

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)1500 View Pricing